Emerging delivery strategy for oncolytic virotherapy.
Mol Ther Oncol
; 32(2): 200809, 2024 Jun 20.
Article
em En
| MEDLINE
| ID: mdl-38845744
ABSTRACT
Oncolytic virotherapy represents a promising approach in cancer immunotherapy. The primary delivery method for oncolytic viruses (OVs) is intratumoral injection, which apparently limits their clinical application. For patients with advanced cancer with disseminated metastasis, systemic administration is considered the optimal approach. However, the direct delivery of naked viruses through intravenous injection presents challenges, including rapid clearance by the immune system, inadequate accumulation in tumors, and significant side effects. Consequently, the development of drug delivery strategies has led to the emergence of various bio-materials serving as viral vectors, thereby improving the anti-tumor efficacy of oncolytic virotherapy. This review provides an overview of innovative strategies for delivering OVs, with a focus on nanoparticle-based or cell-based delivery systems. Recent pre-clinical and clinical studies are examined to highlight the enhanced efficacy of systemic delivery using these novel platforms. In addition, prevalent challenges in current research are briefly discussed, and potential solutions are proposed.
Texto completo:
1
Bases de dados:
MEDLINE
Idioma:
En
Revista:
Mol Ther Oncol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China